Financial Times:
Sources: Dassault Systèmes is in talks to buy drug trial software maker ArisGlobal from Nordic Capital for about $2B, extending its push into life sciences — Potential purchase of ArisGlobal from Swedish buyout group would boost French conglomerate's push into life sciences
